Literature DB >> 22801952

Sclerostin: a candidate biomarker of SCI-induced osteoporosis.

L R Morse1, S Sudhakar, A A Lazzari, C Tun, E Garshick, R Zafonte, R A Battaglino.   

Abstract

UNLABELLED: We assessed several circulating proteins as candidate biomarkers of bone status in men with chronic spinal cord injury. We report that sclerostin is significantly associated with bone mineral content and bone density at all skeletal sites tested. We found no association between bone and any other tested biomarker.
INTRODUCTION: Spinal cord injury results in severe osteoporosis. To date, no circulating biomarker of spinal cord injury (SCI)-induced osteoporosis has been identified. We recently reported that circulating sclerostin is associated with bone density in chronic SCI. In this study, we assessed several circulating proteins as candidate biomarkers of bone in men with chronic SCI.
METHODS: We assessed the relationship between bone mineral content or bone density and the following circulating bone-related proteins: sclerostin, DKK-1, soluble receptor activator of nuclear factor kappa B ligand, osteoprotegerin, osteocalcin, and c-telopeptide in 39 men with chronic SCI and 10 men with no SCI.
RESULTS: After adjusting for age, lower sclerostin levels were significantly associated with lower bone mineral content and bone density at all skeletal sites tested (p = 0.0002-0.03). No other circulating protein was associated with bone mineral content or bone mineral density (p = 0.18-0.99).
CONCLUSION: These findings suggest that circulating sclerostin reflects the severity of bone loss and is a candidate biomarker of osteoporosis severity in chronic SCI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22801952      PMCID: PMC3611240          DOI: 10.1007/s00198-012-2072-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  27 in total

1.  Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy.

Authors:  H N Rosen; A C Moses; J Garber; I D Iloputaife; D S Ross; S L Lee; S L Greenspan
Journal:  Calcif Tissue Int       Date:  2000-02       Impact factor: 4.333

2.  Comparison of the revised 2000 American Spinal Injury Association classification standards with the 1996 guidelines.

Authors:  Steven C Kirshblum; Pietro Memmo; Nancy Kim; Denise Campagnolo; Scott Millis
Journal:  Am J Phys Med Rehabil       Date:  2002-07       Impact factor: 2.159

Review 3.  Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone.

Authors:  P V Hauschka; J B Lian; D E Cole; C M Gundberg
Journal:  Physiol Rev       Date:  1989-07       Impact factor: 37.312

4.  Association between sclerostin and bone density in chronic spinal cord injury.

Authors:  Leslie R Morse; Supreetha Sudhakar; Valery Danilack; Carlos Tun; Antonio Lazzari; David R Gagnon; Eric Garshick; Ricardo A Battaglino
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

5.  A prospective assessment of mortality in chronic spinal cord injury.

Authors:  E Garshick; A Kelley; S A Cohen; A Garrison; C G Tun; D Gagnon; R Brown
Journal:  Spinal Cord       Date:  2005-07       Impact factor: 2.772

6.  Dyspnea during daily activities in chronic spinal cord injury.

Authors:  Noel F Grandas; Nitin B Jain; Joan B Denckla; Robert Brown; Carlos G Tun; Mary Ellen Gallagher; Eric Garshick
Journal:  Arch Phys Med Rehabil       Date:  2005-08       Impact factor: 3.966

7.  Bone mineral density and indexes of bone metabolism in spinal cord injury.

Authors:  S M Szollar; E M Martin; D J Sartoris; J G Parthemore; L J Deftos
Journal:  Am J Phys Med Rehabil       Date:  1998 Jan-Feb       Impact factor: 2.159

8.  Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.

Authors:  Xiaofeng Li; Yazhou Zhang; Heeseog Kang; Wenzhong Liu; Peng Liu; Jianghong Zhang; Stephen E Harris; Dianqing Wu
Journal:  J Biol Chem       Date:  2005-03-18       Impact factor: 5.157

9.  Use of bone biochemical markers with dual-energy x-ray absorptiometry for early determination of bone loss in persons with spinal cord injury.

Authors:  Laurent Maïmoun; Isabelle Couret; Jean-Paul Micallef; Edouard Peruchon; Denis Mariano-Goulart; Michel Rossi; Jean-Louis Leroux; Freddy Ohanna
Journal:  Metabolism       Date:  2002-08       Impact factor: 8.694

10.  Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling.

Authors:  Bingyu Mao; Wei Wu; Gary Davidson; Joachim Marhold; Mingfa Li; Bernard M Mechler; Hajo Delius; Dana Hoppe; Peter Stannek; Carmen Walter; Andrei Glinka; Christof Niehrs
Journal:  Nature       Date:  2002-05-26       Impact factor: 49.962

View more
  18 in total

1.  A Rehabilomics framework for personalized and translational rehabilitation research and care for individuals with disabilities: Perspectives and considerations for spinal cord injury.

Authors:  Amy K Wagner
Journal:  J Spinal Cord Med       Date:  2014-07-16       Impact factor: 1.985

2.  Adiponectin is associated with bone strength and fracture history in paralyzed men with spinal cord injury.

Authors:  C O Tan; R A Battaglino; A L Doherty; R Gupta; A A Lazzari; E Garshick; R Zafonte; L R Morse
Journal:  Osteoporos Int       Date:  2014-07-01       Impact factor: 4.507

3.  Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients.

Authors:  M Invernizzi; S Carda; M Rizzi; E Grana; D F Squarzanti; C Cisari; C Molinari; F Renò
Journal:  Spinal Cord       Date:  2015-04-21       Impact factor: 2.772

Review 4.  Bone loss at the distal femur and proximal tibia in persons with spinal cord injury: imaging approaches, risk of fracture, and potential treatment options.

Authors:  C M Cirnigliaro; M J Myslinski; M F La Fountaine; S C Kirshblum; G F Forrest; W A Bauman
Journal:  Osteoporos Int       Date:  2016-12-05       Impact factor: 4.507

5.  Wheelchair use and lipophilic statin medications may influence bone loss in chronic spinal cord injury: findings from the FRASCI-bone loss study.

Authors:  L R Morse; N Nguyen; R A Battaglino; A J Guarino; D R Gagnon; R Zafonte; E Garshick
Journal:  Osteoporos Int       Date:  2016-07-13       Impact factor: 4.507

6.  Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.

Authors:  L Gifre; S Ruiz-Gaspà; J L Carrasco; E Portell; J Vidal; A Muxi; A Monegal; N Guañabens; P Peris
Journal:  Osteoporos Int       Date:  2017-06-04       Impact factor: 4.507

Review 7.  Clinical utility of serum sclerostin measurements.

Authors:  Bart L Clarke; Matthew T Drake
Journal:  Bonekey Rep       Date:  2013-06-05

8.  Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.

Authors:  Wei Zhao; Xiaodong Li; Yuanzhen Peng; Yiwen Qin; Jiangping Pan; Jiliang Li; Aihua Xu; Michael S Ominsky; Christopher Cardozo; Jian Q Feng; Hua Zhu Ke; William A Bauman; Weiping Qin
Journal:  Calcif Tissue Int       Date:  2018-06-21       Impact factor: 4.333

9.  Prevention and management of osteoporosis and osteoporotic fractures in persons with a spinal cord injury or disorder: A systematic scoping review.

Authors:  Nour Zleik; Frances Weaver; Robert L Harmon; Brian Le; Reshmitha Radhakrishnan; Wanda D Jirau-Rosaly; B Catharine Craven; Mattie Raiford; Jennifer N Hill; Bella Etingen; Marylou Guihan; Michael H Heggeness; Cara Ray; Laura Carbone
Journal:  J Spinal Cord Med       Date:  2018-05-10       Impact factor: 1.985

10.  Ibuprofen use is associated with reduced C-reactive protein and interleukin-6 levels in chronic spinal cord injury.

Authors:  Andrew Park; Dustin Anderson; Ricardo A Battaglino; Nguyen Nguyen; Leslie R Morse
Journal:  J Spinal Cord Med       Date:  2020-06-04       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.